You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Antigens,%20BCMA

Showing 26 - 50 of 882
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Trial in Tianjin (anti-BCMA CAR-T, VRD)

Recruiting
  • Multiple Myeloma
  • anti-BCMA CAR-T
  • VRD
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
May 5, 2023

Multiple Myeloma Trial in Beijing, Suzhou (CAR-BCMA T Cells)

Recruiting
  • Multiple Myeloma
  • CAR-BCMA T Cells
  • Beijing, Beijing, China
  • +1 more
Jan 26, 2023

Multiple Myeloma, Plasma Cell Leukemia Trial in Shanghai (Human BCMA targeted CAR-NK cells injection)

Recruiting
  • Multiple Myeloma
  • Plasma Cell Leukemia
  • Human BCMA targeted CAR-NK cells injection
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Sep 13, 2023

Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,

Recruiting
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Manufactured Anti-BCMA CAR-T cells
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jan 6, 2023

ITP Trial in Suzhou (autologous anti-BCMA chimeric antigen receptor T cells)

Recruiting
  • ITP
  • autologous anti-BCMA chimeric antigen receptor T cells
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Mar 31, 2022

Multiple Myeloma Trial in Tianjin (anti-BCMA CAR-T)

Recruiting
  • Multiple Myeloma
  • anti-BCMA CAR-T
  • Tianjin, Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
May 4, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Hangzhou (BCMA CAR-NK, Cyclophosphamide, Fludarabine

Recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • BCMA CAR-NK
  • +2 more
  • Hangzhou, Zhejiang, China
  • +1 more
Feb 17, 2023

Relapsed, Refractory Multiple Myeloma Trial in Milwaukee (RAPA-201 Autologous T cells)

Recruiting
  • Relapsed, Refractory Multiple Myeloma
  • RAPA-201 Autologous T cells
  • Milwaukee, Wisconsin
    Medical College of Wisconsin
Dec 28, 2021

Relapsed/Refractory Multiple Myeloma Trial in Xi'an (LUCAR-B68 cells product)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • LUCAR-B68 cells product
  • Xi'an, Shaanxi, China
    Second Affiliated Hospital of Xi'an Jiaotong University
Aug 10, 2022

Relapse Multiple Myeloma, Refractory Multiple Myeloma Trial in Hangzhou (BCMA Targeted CAR T-cells)

Recruiting
  • Relapse Multiple Myeloma
  • Refractory Multiple Myeloma
  • BCMA Targeted CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Medical College, Zhejiang Univers
Jun 18, 2022

Multiple Myeloma Trial in Boston, Milwaukee (CART-ddBCMA)

Not yet recruiting
  • Multiple Myeloma
  • CART-ddBCMA
  • Boston, Massachusetts
  • +1 more
Jul 7, 2022

Myeloma Multiple Trial (Off Drug Surveillance)

Not yet recruiting
  • Myeloma Multiple
  • Off Drug Surveillance
  • (no location specified)
Jun 27, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Hangzhou (APRIL CAR-T cells)

Recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • APRIL CAR-T cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital，College of Medicine, Zhejiang Univ
May 3, 2022

Hypersensitivity Pneumonitis, Nasal Mucosal Disorder Trial in Cairo (nasal endoscopy)

Completed
  • Hypersensitivity Pneumonitis
  • Nasal Mucosal Disorder
  • nasal endoscopy
  • Cairo, Egypt
    Kasr alainy school of medicine
Feb 9, 2023

Multiple Myeloma Trial in Zhengzhou (PD1-BCMA-CART)

Not yet recruiting
  • Multiple Myeloma
  • PD1-BCMA-CART
  • Zhengzhou, Henan, China
    First Affliated Hospital of Zhengzhou University
May 15, 2022

Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)

Not yet recruiting
  • HIV Seropositivity
  • +2 more
  • HIV Ag +Ab Assay Kit (Sysmex)
  • (no location specified)
Aug 1, 2023

Relapsed/Refractory, Systemic Lupus Erythematosus (SLE) Trial in Zhongshan (BCMA-CD19 cCAR T cells)

Recruiting
  • Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)
  • BCMA-CD19 cCAR T cells
  • Zhongshan, Guangdong, China
    Zhongshan People's Hospital
Jul 23, 2022

Multiple Myeloma Trial in Hangzhou, Wuhan (CART-BCMA)

Recruiting
  • Multiple Myeloma
  • Hangzhou, China
  • +1 more
Apr 23, 2022

Antigens or Therapeutic Agents on in Vitro Human Intestinal

Recruiting
  • Intestine Disease
    • Erlangen, Germany
      Department of Medicine 1, Hector Center for Nutrition, Exercise
    Jan 12, 2023

    Relapsed/Refractory Multiple Myeloma Trial in Philadelphia (Cevostamab)

    Not yet recruiting
    • Relapsed/Refractory Multiple Myeloma
    • Philadelphia, Pennsylvania
      Hospital of the University of Pennsylvania
    Apr 7, 2023

    Multiple Myeloma, Refractory, Multiple Myeloma in Relapse Trial in Cleveland (Autologous CAR-T cell therapy expressing the

    Not yet recruiting
    • Multiple Myeloma, Refractory
    • Multiple Myeloma in Relapse
    • Autologous CAR-T cell therapy expressing the BAFF-ligand.
    • Cleveland, Ohio
      University Hospitals Seidman Cancer Center
    Jan 11, 2023

    Multiple Myeloma Trial in Tianjin (Autologous hematopoietic stem cell transplantation, C-CAR088)

    Recruiting
    • Multiple Myeloma
    • Autologous hematopoietic stem cell transplantation
    • C-CAR088
    • Tianjin, Tianjin, China
      Institute of Hematology & Blood Diseases Hospital
    Nov 21, 2022

    Multiple Myeloma Trial in Worldwide (PHE885)

    Recruiting
    • Multiple Myeloma
    • PHE885
    • VIC, Melbourne, Australia
    • +4 more
    Jul 20, 2022

    Multiple Myeloma Trial in Worldwide (Elranatamab (PF-06863135))

    Active, not recruiting
    • Multiple Myeloma
    • Elranatamab (PF-06863135)
    • Beverly Hills, California
    • +75 more
    Oct 4, 2022

    Multiple Myeloma Trial in Philadelphia (BCMA CART + huCART19, CART BCMA or CART BCMA + huCART19, Single-dose infusion of CART

    Active, not recruiting
    • Multiple Myeloma
    • BCMA CART + huCART19
    • +2 more
    • Philadelphia, Pennsylvania
      Univ. of Pennsylvania
    Jul 11, 2022